How Mirvetuximab Soravtansine Has Impacted Clinical Management of Ovarian Cancer
Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.
Author(s): Sponsored by Novartis
The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.
As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic…
Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.
The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.
Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.
The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.
Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.
Drs Camidge and Lin discussed Dr Lin’s work with brain metastases and her role in developing targeted therapies for breast cancer.